Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
ABB has introduced significant advancements to the power simulation models for its ABB UNITROL 1000 Automatic Voltage Regulators (AVR).
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results